Matches in Wikidata for { <http://www.wikidata.org/entity/Q93230972> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q93230972 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q93230972 description "im März 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q93230972 description "scientific article published on 26 March 2020" @default.
- Q93230972 description "wetenschappelijk artikel" @default.
- Q93230972 description "наукова стаття, опублікована 26 березня 2020" @default.
- Q93230972 name "Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook" @default.
- Q93230972 name "Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook" @default.
- Q93230972 type Item @default.
- Q93230972 label "Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook" @default.
- Q93230972 label "Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook" @default.
- Q93230972 prefLabel "Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook" @default.
- Q93230972 prefLabel "Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook" @default.
- Q93230972 P1433 Q93230972-0A421D78-EAC5-4932-84CB-564330B0FE0B @default.
- Q93230972 P1476 Q93230972-A32CCD70-8418-4A35-A8DB-4AB06C6E9567 @default.
- Q93230972 P2093 Q93230972-3F4C5C81-612C-472C-8EB4-0D8E142A976F @default.
- Q93230972 P2093 Q93230972-43AC47AD-D39E-4EE0-914C-78E3FEFFFFC0 @default.
- Q93230972 P2093 Q93230972-718E1B00-EDF6-4BA1-A341-6815AD741B2A @default.
- Q93230972 P2093 Q93230972-7DE0A78F-4706-4011-B73D-F129E9ECED0D @default.
- Q93230972 P2093 Q93230972-92E9B1F0-C5AA-41E1-AE20-44B543A65EF3 @default.
- Q93230972 P2093 Q93230972-ED8232A4-7624-4E7F-84BD-A2F7717320C0 @default.
- Q93230972 P2093 Q93230972-F10B5F9F-1E51-47C1-A9EB-AD0700B05B63 @default.
- Q93230972 P304 Q93230972-35A170B7-1F71-4965-86EB-4A42D3034738 @default.
- Q93230972 P31 Q93230972-24946AC0-979D-4CEA-8FE1-F2459E6F281A @default.
- Q93230972 P31 Q93230972-7b160692-cc76-4db4-8f92-5374e6023859 @default.
- Q93230972 P356 Q93230972-65FBF560-918C-46D9-AEB8-FC5DFEFACF3F @default.
- Q93230972 P478 Q93230972-A3164345-2E8D-42B3-B653-2E57EC18AB93 @default.
- Q93230972 P577 Q93230972-28061B11-AEB5-460F-B51B-0AEB5801262B @default.
- Q93230972 P698 Q93230972-C2ED4656-1384-4B82-9127-4537916A2955 @default.
- Q93230972 P921 Q93230972-06BE23E4-8AC4-48A3-9886-5701E19201AC @default.
- Q93230972 P356 J.CTRV.2020.102017 @default.
- Q93230972 P698 32335505 @default.
- Q93230972 P1433 Q1955762 @default.
- Q93230972 P1476 "Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook" @default.
- Q93230972 P2093 "Alan B Sandler" @default.
- Q93230972 P2093 "David Miles" @default.
- Q93230972 P2093 "Herbert I Hurwitz" @default.
- Q93230972 P2093 "Josep Garcia" @default.
- Q93230972 P2093 "Olivier L Chinot" @default.
- Q93230972 P2093 "Regula Deurloo" @default.
- Q93230972 P2093 "Robert L Coleman" @default.
- Q93230972 P304 "102017" @default.
- Q93230972 P31 Q13442814 @default.
- Q93230972 P31 Q7318358 @default.
- Q93230972 P356 "10.1016/J.CTRV.2020.102017" @default.
- Q93230972 P478 "86" @default.
- Q93230972 P577 "2020-03-26T00:00:00Z" @default.
- Q93230972 P698 "32335505" @default.
- Q93230972 P921 Q413299 @default.